30 closest matches · ranked by relevance
Acute Leukemia · Chronic Myelogenous Leukemia · Myelodysplasia
Primary: Percentage of Participants With GVHD/Relapse or Progression-free Survival (GRFS) — 35.5; 27.2; 44.1 percentage of participants
Acute Graft Versus Host Disease
Primary: Percentage of Participants With Evidence of Acute Graft Versus Host Disease (aGVHD), Post Transplant — 43; 89 percentage of participants
Graft vs Host Disease · Immune System Disorders
Primary: Number of Complete Response (CR) at Day 28 of Therapy — 12; 27; 25; 16 participants
Graft-versus-Host Disease · Immune System Disorders
Primary: GVHD-free Survival — 60; 69; 59; 47 participants
Hematologic Malignancies
Primary: GVHD-free Relapse-Free Survival — 19.3 percentage of subjects
Hematological Malignancies
Primary: Incidence of Acute GVHD — 45.0 percentage of participants
Leukemia · Lymphoma · Myelodysplastic Syndrome
Primary: The Cumulative Incidence of Grade II-IV Acute GVHD up to Day 100 After Stem Cell Infusion — 32 Percentage of participants
Acute Lymphoblastic Leukemia · Acute Myeloid Leukemia · Aggressive Non-Hodgkin Lymphoma
Primary: Number of Patients With Grades II-IV Acute GVHD — 39; 22; 3 Participants
Acute Graft Versus Host Disease
Primary: Number of Participants With Complete Response (CR) — 34 Participants
Graft Versus Host Disease
Primary: Distribution of Acute GVHD Grades (MAGIC Criteria) at Time of PET/CT Scan — 0; 2; 0; 0 Participants
Graft-Versus-Host Disease (GVHD) Acute on Chronic
Primary: Number (Percentage) of Patients at Each Dosing Cohort Who Experience no Toxicity and in Whom Graft Versus Host Disease (GVHD) is Stable or Improved — 6; 2; 2 Participants
Chronic GVHD
Primary: Proportion of Participants With Treatment Success — 33; 35; 33; 37 Participants — p=0.63
Graft Versus Host Disease · Recurrent Adult Acute Lymphoblastic Leukemia
Primary: Mean Cumulative Prednisone Dose (mg/kg) Over 42 Days From the Start of Treatment — 22.2; 27.1; 38.4; 41.3 milligrams per kilogram — p=0.08
Graft Vs Host Disease · Graft-versus-host-disease · Acute-graft-versus-host Disease
Primary: Grades II-IV aGVHD — 11 Participants
Chronic Graft Versus Host Disease
Primary: Number of Participants With an Overall Response at Week 28 — 20; 14 Participants — p=0.373
Acute Graft Versus Host Disease
Primary: The Percentage of Patients Who Progress Within 28 Days of Initiation of Etanercept Treatment — 29 percentage of patients
Blood Cancer · Leukemia
Primary: Acute Graft vs Host Disease (GvHD) — 2.7 percentage of participants
Adult Acute Lymphoblastic Leukemia · Adult Acute Myeloid Leukemia · Adult Diffuse Large B-Cell Lymphoma
Primary: Number of Patients With Grade II-IV Acute Graft Versus Host Disease (GVHD) — 15; 12 Participants
Hematological Malignancies
Primary: Incidence of Clinician-diagnosed Chronic GVHD at One and Two Years — 38; 48 percentage of participants
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable · Previously Treated Myelodysplastic Syndrome · Refractory Chronic Lymphocytic Leukemia
Primary: Number of Participants With Grades II-IV Acute GVHD — 44; 34; 32 Participants — p=0.09
Accelerated Phase Chronic Myelogenous Leukemia · Adult Acute Lymphoblastic Leukemia in Remission · Adult Acute Megakaryoblastic Leukemia (M7)
Primary: Chronic GVHD Requiring Systemic Immunosuppressive Treatment — 16 percent of patients
Accelerated Phase Chronic Myelogenous Leukemia · Adult Acute Lymphoblastic Leukemia in Remission · Adult Acute Myeloid Leukemia in Remission
Primary: Incidence of Grade III/IV GVHD — 2; 4 Participants
Hematopoietic Stem Cell Transplantation
Primary: Number of Subjects Not Experiencing Grade II-IV Acute Graph Versus Host Disease (aGVHD) — 3; 18; 0 Participants
Chronic Myeloproliferative Disorders · Leukemia · Lymphoma
Primary: Incidence of Acute Graft-versus-host Disease (GVHD) — 44.7 percentage of participants
Graft Versus Host Disease
Primary: Number of Participants Experiencing Treatment Success — 8 Participants
Leukemia · Lymphoma · Myelodysplastic Syndrome
Primary: Grade II-IV Acute GVHD — 30 percentage of participants
Graft Versus Host Disease
Primary: Day 56 Treatment Success — 57; 72; 43; 47 percentage of participants
Chronic Myeloproliferative Disorders · Graft Versus Host Disease · Infection
Primary: Cumulative Incidence of Grade II-IV Acute Graft-Versus-Host Disease (GVHD) at Day 100 — 37.3 Percentage of patients developing aGVHD
Leukemia, Myelocytic, Acute · Leukemia, Lymphocytic, Acute · Leukemia, Myeloid, Chronic
Primary: Rate of Grades II-IV Acute GVHD-free Survival — 67; 62 percentage of participants
Chronic Graft Versus Host Disease
Primary: Feasibility of Enrolling Patients — 21 Participants